Tekturna Launch Anticipated “Very Quickly” Following Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.
You may also be interested in...
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.
Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007
DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.